Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Inclusion Criteria: * Chronic hepatitis C genotype 1. * Failed to respond to ≥12 weeks of peginterferon and ribavirin (\<2 log10 drop in Hepatitis C Virus Ribonucleic Acid (HCV RNA) at week 12 or detectable Hepatitis C Virus Ribonucleic Acid (HCV RNA) at week 24). Exclusion Criteria: * Females of child-bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active. * Males whose female partners are either pregnant or of child-bearing potential or not using birth control and are sexually active. * Other causes of liver disease including autoimmune hepatitis. * Transplant recipients receiving immune suppression therapy. * Screening tests positive for Anti-Hepatitis A Virus Immunoglobulin M Antibody (anti-HAV IgM Ab), Hepatitis B's antigen (HBsAg), Anti-Hepatitis B core antigen Immunoglobulin M Antibody (anti-HBc IgM Ab) or Anti-Human Immunodeficiency Virus Antibody (anti-HIV Ab). * Decompensated cirrhosis, history of variceal bleeding, ascites, hepatic encephalopathy, Child-Turcotte-Pugh (CTP) score \>6 or Model for End-stage Liver Disease (MELD) score \>8. * Alcohol consumption of \>40 grams per day or an alcohol use pattern that will interfere with the study. * Absolute neutrophil count \<1500 cells/mm3; platelet count \<135,000 cells/mm3; hemoglobin \<12 g/dL for women and \<13 g/dL for men; or serum creatinine concentration ≥1.5 times Upper Limit of Normal (ULN). * Hypothyroidism or hyperthyroidism not effectively treated with medication. * Hemoglobin A1C (HgbA1c) \>7.5 or history of diabetes mellitus. * Body Mass Index (BMI) \>28. * History or other clinical evidence of significant or unstable cardiac disease. * History or other clinical evidence of chronic pulmonary disease associated with functional impairment. * Serious or severe bacterial infection(s). * Ulcerative or hemorrhagic/ischemic colitis. * Pancreatitis. * History of severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization. * History of uncontrolled severe seizure disorder. * Requires concomitant theophylline or methadone. * History of immunologically mediated disease requiring more than intermittent anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids. * History or other evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. * Hemoglobinopathies. * History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or ribavirin tablets.